Microbot Medical (NASDAQ:MBOT) Issues Earnings Results
Microbot Medical (NASDAQ:MBOT - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02), Zacks reports.
Shares of NASDAQ MBOT traded down $0.01 during mid-day trading on Tuesday, reaching $1.59. 759,230 shares of the company were exchanged, compared to its average volume of 1,767,746. Microbot Medical has a 52 week low of $0.82 and a 52 week high of $3.38. The company's 50 day moving average price is $1.75 and its 200 day moving average price is $1.30. The stock has a market capitalization of $55.24 million, a PE ratio of -1.99 and a beta of 1.60.
Separately, HC Wainwright raised their target price on shares of Microbot Medical from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, January 24th.
Read Our Latest Report on MBOT
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
